Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

Area of Science:

• Oncolytic virotherapy
• Molecular oncology
• Gene therapy

Background:

• Retinoblastoma tumor suppressor protein (pRB) pathway is often dysregulated in cancer.
• Adenoviruses are DNA viruses with potential for oncolytic applications.
• Selective replication in tumor cells is a key goal for oncolytic virus safety and efficacy.

Purpose of the Study:

• To engineer a human adenovirus, ONYX-411, with tumor-selective replication.
• To evaluate the dependency of viral replication on the pRB pathway status.
• To assess the efficacy of ONYX-411 in vitro and in vivo.

Main Methods:

• Engineering of a human adenovirus (ONYX-411) for pRB pathway-dependent replication.
• In vitro studies assessing viral gene expression, DNA replication, and cell killing in normal and tumor cells.
• In vivo studies using tumor-bearing animal models to evaluate systemic administration and tumor targeting.

Main Results:

• ONYX-411 demonstrated significantly reduced viral gene expression and DNA replication in cells with a functional pRB pathway.
• Replication profile in normal cells mimicked non-replicating adenoviruses.
• ONYX-411 exhibited comparable viral life cycle and tumor cell killing activity to wild-type adenovirus in tumor cells.
• Effective tumor cell killing was observed in vitro and in vivo after systemic administration.

Conclusions:

• ONYX-411 is a human adenovirus engineered for selective replication in tumor cells based on pRB pathway status.
• The oncolytic virus shows a promising safety profile due to restricted replication in normal tissues.
• ONYX-411 holds potential as an effective oncolytic agent for cancer therapy.